Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Severe erectile dysfunction is a marker for hyperprolactinemia

International Journal of Impotence Research volume 13, pages 176–182 (2001)Cite this article

Abstract

The need for routine prolactin (PRL) measurement in the initial evaluation of erectile dysfunction (ED) has been questioned because of the low rate of hyperprolactinemia (HP) in these men and the costs involved. In addition, it is widely thought that sexual desire problems are a good clinical marker for HP and/or low testosterone in men with ED. Within a 15-month period, 844 consecutive PRL and sexual hormone determinations were conducted in men at the Kingston General Hospital. Of these patients, 138 were comprehensively evaluated at the first visit for ED and completed the International Index of Erectile Function (IIEF). In the 138 patients, 2.2% had severe hyperprolactinemia (>35 ng/ml), within the range of 1–5% previously reported. No correlation between initial prolactin value and the sexual desire domain or the erectile function domain (EFD) of the IIEF was found for this population. However, all cases of severe HP were found to occur in men who scored less than 10 in the EFD of the IIEF. Low libido is widely accepted as a marker of HP. In this study, HP was found in patients not reporting major problems with a desire disorder. Clinically significant HP may be reliably found with routine biochemical evaluation and in this series was not detected in patients with EFD scores above 10. A routine PRL measurement is inexpensive and early detection of a serious and treatable disease may afford greater therapeutic success.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Akpunonu BE et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 1994 9, 336–338.

    Article  CAS  Google Scholar 

  2. Buvat J, Lemaire A. . Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997 158, 1764–1767.

    Article  CAS  Google Scholar 

  3. Nickel JC et al. Endocrine dysfunction in impotence: incidence, significance, and cost-effective screening. J Urol 1984 132, 40–43.

    Article  CAS  Google Scholar 

  4. Seftel AD. . Editorial: erectile dysfunction—the paradigm changes but the challenges remain. J Urol 1997 156, 1768–1769.

    Article  Google Scholar 

  5. Garg RK, Khaishgi A, Dandona P. . Is management with sildenafil changing clinical practice? Lancet 1999 353, 375–376.

    Article  CAS  Google Scholar 

  6. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dyfunction. Urology 1997 49, 822–830.

    Article  CAS  Google Scholar 

  7. Padma-Nathan H. . Diagnostic and treatment strategies for erectile dysfunction: the ‘Process of Care’ model. Int J Impot Res 2000 12(Suppl 4), S119–S121.

    Article  Google Scholar 

  8. NIH Consensus Development Panel on Impotence. . Impotence. JAMA 1993 270, 83–90.

    Article  Google Scholar 

  9. Johnson AR, Jarow JP. . Is routine endocrine testing of impotent men necessary? J Urol 1992 147, 1542–1544.

    Article  Google Scholar 

  10. Foster RS et al. Role of serum prolactin determination in evaluation of impotent patient. Urology 1990 XXXV1, 499–501.

    Article  Google Scholar 

  11. Cappelleri JC et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999 54, 346–349.

    Article  CAS  Google Scholar 

  12. Sinha YN. . Structural variants of prolactin: occurrence and physiological significance. Endocrine Rev 1995 16, 354–369.

    Article  CAS  Google Scholar 

  13. Leite V et al. Characterization of big–big prolactin in patients with hyperprolactinemia. Clin Endocrinol 1992 37, 365–372.

    Article  CAS  Google Scholar 

  14. Guay AT, Sabharwal P, Varma S, Malarkey WB. . Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 1996 81, 2512–2514.

    CAS  PubMed  Google Scholar 

  15. Tritos NA, Guay AT, Malarkey WB. . Asymptomatic ‘big’ hyperprolactinemia in two men with pituitary adenomas. Eur J Endocrinol 1998 138, 82–85.

    Article  CAS  Google Scholar 

  16. Cavaco B et al. Hyperprolactinemia due to big–big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999 22, 203–208.

    Article  CAS  Google Scholar 

  17. Kropman RF et al. Routine endocrine screening in impotence: significance and cost-effectiveness. Int J Impot Res 1991 3, 87.

    Google Scholar 

  18. Maatman TJ, Montague DK. . Routine endocrine screening in impotence. Urology 1986 27, 499.

    Article  CAS  Google Scholar 

  19. Leonard MP, Nickel CJ, Morales A. . Hyperprolactinemia and impotence: why, when, and how to investigate. J Urol 1989 142, 992.

    Article  CAS  Google Scholar 

  20. Zonszein J. . Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin N Am 1995 22, 789–802.

    CAS  Google Scholar 

  21. Besser GM et al. Clinical and therapeutic aspects of hyperprolactinemia. In: MacLeod RM, Thorner MO, Scapagnini U (eds). Prolactin. Basic and Clinical Correlates Liviana Press: Padova 1985 833–847.

    Google Scholar 

  22. Carter JN et al. Prolactin-secreting tumors and hypogonadism in 22 men. New Engl J Med 1978 299, 847–852.

    Article  CAS  Google Scholar 

  23. Chan-Tack KM. . Oral sildenafil in erectile dysfunction. Lancet 1998 352, 1557.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The assistance of Dr Michael J Raymond (Chief, Clinical Chemistry), and the financial support from the Queen's University Dean of Medicine, is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Queen's University, Kingston General Hospital, Ontario, Canada

    AM Johri, JPW Heaton & A Morales

Authors
  1. AM Johri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JPW Heaton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johri, A., Heaton, J. & Morales, A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 13, 176–182 (2001). https://doi.org/10.1038/sj.ijir.3900675

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900675

Keywords

This article is cited by

Search

Advanced search

Quick links